Clinical Trials Directory

Trials / Completed

CompletedNCT05225337

Time Restricted Eating for the Treatment of Type 2 Diabetes

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
75 (actual)
Sponsor
University of Illinois at Chicago · Academic / Other
Sex
All
Age
18 Years – 80 Years
Healthy volunteers
Not accepted

Summary

Innovative lifestyle strategies to treat type 2 diabetes (T2DM) are critically needed. At present, daily calorie restriction (CR) is the main diet prescribed to patients with T2DM for weight loss. However, many patients find it difficult to adhere to CR because calorie intake must be vigilantly monitored every day. In light of these problems with CR, another approach that limits timing of food intake, instead of number of calories consumed, has been developed. This diet is called "time restricted eating" (TRE) and involves confining the period of food intake to 6-8 h per day. TRE allows individuals to self-select foods and eat ad libitum during a large part of the day, which greatly increases compliance to these protocols. Recent findings show that TRE is effective for weight loss and improved glycemic control in patients with obesity and prediabetes. However no long-term randomized controlled trial has examined whether TRE is safe and effective for patients with obesity and T2DM. This study is a 6-month randomized, controlled trial that aims to compare the effects of TRE (eating all food between 12:00 pm to 8:00 pm, without calorie counting), versus CR (25% energy restriction daily), and a control group eating over a period of 10 or more hours per day, on change in body weight (%), glycemic control, and cardiometabolic risk factors, in adults with obesity and T2DM.

Conditions

Interventions

TypeNameDescription
OTHERTime restricted feeding (TRF)8-h eating window Ad libitum food intake from 12-8 pm every day Fasting from 8-12 pm every day (16-h fast)
OTHERDaily calorie restriction25% energy restriction every day Diet counseling provided

Timeline

Start date
2022-02-10
Primary completion
2023-04-01
Completion
2024-11-25
First posted
2022-02-04
Last updated
2024-11-27

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT05225337. Inclusion in this directory is not an endorsement.